New daily pill aims to tame psoriatic arthritis symptoms
NCT ID NCT07706530
First seen Jul 15, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This phase 2 trial tests an experimental oral drug called CBP-0276 in adults with active psoriatic arthritis, a condition causing joint pain, swelling, and skin plaques. Participants receive either a low dose (200 mg), a high dose (800 mg), or a placebo daily for 24 weeks. The main goal is to see if the drug reduces symptoms by at least 20% compared to placebo, with additional checks on how quickly and strongly symptoms improve.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called CBP-0276
- What this could lead to
- If successful, this could point toward a new daily pill to control joint and skin symptoms in people with psoriatic arthritis.
- What could go wrong
- This is a mid-stage trial with a relatively small number of participants, so results may not confirm effectiveness or safety. The drug may cause side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIC PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Innovacion y Desarrollo en Ciencias de la Salud (IDeCSa)
Mexico City, Mexico City, 14090, Mexico
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••